AI Takes Out the Trash: Largest U.S. Recycling Project to Extend Landfill Life for Virginia Residents
21.11.2025 13:30:00 CET | Business Wire | Press Release
The Southeastern Public Service Authority of Virginia (“SPSA”), the regional waste authority for South Hampton Roads, has signed a 20-year contract with Commonwealth Sortation LLC, an affiliate of AMP Robotics Corporation (together, “AMP”), to provide solid waste processing services for SPSA’s eight member communities and their 1.2 million residents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120330758/en/
Building on a nearly two-year pilot project in Portsmouth—which featured an AMP ONE™ system capable of processing up to 150 tons of locally sourced municipal solid waste (“MSW”) per day—AMP will now scale its technology region-wide. Under this long-term partnership, which will facilitate the largest recycling project in the country, AMP will deploy additional MSW sortation lines and an organics management system capable of processing 540,000 tons annually to divert half of the waste SPSA brings to AMP facilities.
AMP’s AI-based sorting technology uses cameras, robotics, and pneumatic jets to detect and remove recyclables and organics from bagged trash. With AMP’s solution, SPSA can:
- Extend the life of its landfill;
- Decrease long-term collection and disposal costs for communities; and
- Adapt to evolving community needs, including organic waste management, to better support a growing, thriving region.
Dennis Bagley, executive director of SPSA, said, “This project will enable us to improve how we manage waste from the communities we serve, turning all 1.2 million residents into active recyclers, while doubling the life of our landfill. This technology is demonstrating that there are effective ways to recover valuable resources from the trash, and we're proud to be on the cutting edge of providing high-quality and transparent waste management services.”
Partnering with AMP guarantees the region will recycle 20% of its waste—more than double the recycling rate of the highest-performing community in the region—while eliminating the need for separate recycling facilities and trucks to process most recyclables. SPSA’s own waste characterization study found high rates of recyclables, mainly plastics and metals, in the Hampton Roads waste stream—even in communities with curbside recycling.
Tim Stuart, CEO of AMP, said, “Recycling rates have been stuck for both communities and the nation at large for the last decade and a half. Projects like this one offer a new model for recycling, one that’s better aligned with local waste infrastructure. Our approach to processing MSW will significantly reduce the volume of waste SPSA must landfill, enable the creation of useful end products, and do so with meaningfully lower emissions levels than those resulting from competing solutions. At the end of the day, it’s a win-win for all involved, and will serve as a model for other communities seeking to adopt more sustainable waste management practices.”
Notably, this solution will allow all residential and commercial waste to be collected in a single bin. AMP will leverage two sortation facilities in Portsmouth to extract recyclables (plastics, metals, and fiber) and organics, while collaborating with SPSA to dispose of the residuals. A third facility, adjacent to a sortation facility on Victory Boulevard, will transform the captured organics via indirect heating into biochar, a charcoal-like substance that sequesters carbon.
By creating processing capacity at multiple sites instead of centralizing at one location, SPSA gains operational resilience, reducing downtime risk and ensuring reliable landfill diversion. Beyond extending the life of SPSA’s landfill, each diverted ton of MSW reduces or sequesters more than 0.7 tons of carbon dioxide-equivalent greenhouse gases—equating to more than 378,000 tons of carbon dioxide avoided or removed annually across SPSA’s processable waste—roughly the same as taking more than 88,000 cars off the road for a year.
AMP, which is backed by investors including Sequoia Capital, Congruent Ventures, XN, Blue Earth Capital, California State Teachers’ Retirement System (CalSTRS), and Microsoft Climate Innovation Fund, expects to create approximately 100 jobs and build numerous transferable skills in the local workforce. Unlike legacy waste processing facilities where the workforce is concentrated in manual sorting roles, AMP’s solution relies on production operators who have the opportunity to learn how to optimize the technology and automated systems they manage.
About AMP™
AMP is applying AI-powered sortation at scale to modernize the world's recycling infrastructure and maximize the value in waste. AMP designs, builds, and operates advanced, cost-competitive facilities to process single-stream recycling and municipal solid waste. The company’s AI platform has identified more than 200 billion items and its systems have processed 2.8 million tons of recyclables. With three full-scale facilities and more than 400 AI systems deployed across North America, Asia, and Europe, AMP’s technology offers a transformational solution to waste sortation and changes the fundamental economics of recycling.
About SPSA
The Southeastern Public Service Authority (SPSA) manages solid waste services for more than 1.2 million residents across eight southeastern Virginia communities: Chesapeake, Franklin, Isle of Wight County, Norfolk, Portsmouth, Southampton County, Suffolk, and Virginia Beach. Established in 1976, SPSA is dedicated to delivering environmentally responsible, cost-effective waste solutions. Learn more at www.spsava.gov or follow SPSA on Facebook, LinkedIn, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251120330758/en/
Contacts
Media Contact
Carling Spelhaug
carling@ampsortation.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom